Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Beigene Ltd.
Headquarters: Cambridge, MA, United States of America
Website: http://www.beigene.com
Year Founded: 2010
Status: Public
Industry Sector: HealthTechnology
CEO: John V. Oyler, MBA
Number Of Employees: 11,000
Enterprise Value: $17,890,931,217
PE Ratio: -40.91
Exchange/Ticker 1: NASDAQ:ONC
Exchange/Ticker 2: HKEX:6160
Latest Market Cap: $24,761,939,968
BioCentury | Mar 26, 2025
Discovery & Translation
Science Spotlight: New insight into LAG3’s checkpoint function
BioCentury’s roundup of translational innovations also includes a blood-based T cell assay for T1D, a degrader using a new E3 ligase, and papers from newcos
BioCentury | Mar 26, 2025
Finance
Early lessons from the NewCo Model
Panelists on a Capital Markets Preview webinar from BioCentury and Oppenheimer debate the hottest trend in dealmaking
BioCentury | Feb 19, 2025
Deals
Biogen takes territorial rights to Stoke’s Dravet program: Deals Report
Plus: Antithrombotic comes back to Novartis via deal for Anthos, Newleos debuts with portfolio of Roche assets, and more
BioCentury | Jan 29, 2025
Guest Commentary
Winning over Wall Street: Biotechs’ comeback playbook — a Guest Commentary by Jami Rubin
Advice for CEOs and CFOs as they navigate the year ahead
BioCentury | Jan 11, 2025
Management Tracks
Faces in new places ahead of JPM: Rubin joining Guggenheim
Week’s management moves include new venture partners at Frazier and updates from Beigene, Intellia and more
BioCentury | Jan 10, 2025
Data Byte
FDA’s new and supplemental approvals in December
Agency approves at least nine new therapies; adds new indications or patient populations to a dozen marketed drugs
BioCentury | Jan 7, 2025
Management Tracks
John Finn named CSO of Basecamp
Plus: Iambic hires Michael Secora and updates from Septerna, Beigene, Perspective, Halia and more
BioCentury | Nov 20, 2024
Product Development
Biotechs now match pharma for FDA approvals
Half of FDA approvals are sponsored by biotechs; almost all are marketing in the U.S. themselves
BioCentury | Nov 19, 2024
Politics, Policy & Law
As Congress considers Biosecure, report says WuXi companies low-risk
Rhodium Group report suggests Congress focus on economic rather than military threats from China biotech
BioCentury | Nov 15, 2024
Product Development
BeiGene’s globalization story comes of age
New name, plans to domicile in Switzerland reflect maturation of oncology player
Items per page:
1 - 10 of 443